182 related articles for article (PubMed ID: 34386661)
41. The Effect of Dietary Protein Concentration on the Fecal Microbiome and Serum Concentrations of Gut-Derived Uremic Toxins in Healthy Adult Cats.
Summers S; Quimby J; Gagné J; Lappin M
Vet Sci; 2023 Aug; 10(8):. PubMed ID: 37624284
[TBL] [Abstract][Full Text] [Related]
42. Uremic Toxin Clearance and Cardiovascular Toxicities.
Mair RD; Sirich TL; Meyer TW
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29865226
[TBL] [Abstract][Full Text] [Related]
43. Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease.
Bush KT; Singh P; Nigam SK
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271169
[TBL] [Abstract][Full Text] [Related]
44. Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome.
Lekawanvijit S
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30200452
[TBL] [Abstract][Full Text] [Related]
45. Normal and pathologic concentrations of uremic toxins.
Duranton F; Cohen G; De Smet R; Rodriguez M; Jankowski J; Vanholder R; Argiles A;
J Am Soc Nephrol; 2012 Jul; 23(7):1258-70. PubMed ID: 22626821
[TBL] [Abstract][Full Text] [Related]
46. Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease.
Zeng YQ; Dai Z; Lu F; Lu Z; Liu X; Chen C; Qu P; Li D; Hua Z; Qu Y; Zou C
Oncotarget; 2016 Apr; 7(14):17468-78. PubMed ID: 27003359
[TBL] [Abstract][Full Text] [Related]
47. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets.
Lim YJ; Sidor NA; Tonial NC; Che A; Urquhart BL
Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33668632
[TBL] [Abstract][Full Text] [Related]
48. Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes.
Wu W; Bush KT; Nigam SK
Sci Rep; 2017 Jul; 7(1):4939. PubMed ID: 28694431
[TBL] [Abstract][Full Text] [Related]
49. Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial.
McFarlane C; Krishnasamy R; Stanton T; Savill E; Snelson M; Mihala G; Kelly JT; Morrison M; Johnson DW; Campbell KL
Nutrients; 2021 Dec; 13(12):. PubMed ID: 34960037
[TBL] [Abstract][Full Text] [Related]
50. Synbiotics Alleviate the Gut Indole Load and Dysbiosis in Chronic Kidney Disease.
Yang CY; Chen TW; Lu WL; Liang SS; Huang HD; Tseng CP; Tarng DC
Cells; 2021 Jan; 10(1):. PubMed ID: 33435396
[TBL] [Abstract][Full Text] [Related]
51. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review.
Vanholder R; Schepers E; Pletinck A; Nagler EV; Glorieux G
J Am Soc Nephrol; 2014 Sep; 25(9):1897-907. PubMed ID: 24812165
[TBL] [Abstract][Full Text] [Related]
52. Effect of cranberry supplementation on toxins produced by the gut microbiota in chronic kidney disease patients: A pilot randomized placebo-controlled trial.
Teixeira KTR; Moreira LSG; Borges NA; Brum I; de Paiva BR; Alvarenga L; Nakao LS; Leal VO; Carraro-Eduardo JC; Rodrigues SD; Lima JD; Ribeiro-Alves M; Mafra D
Clin Nutr ESPEN; 2022 Feb; 47():63-69. PubMed ID: 35063244
[TBL] [Abstract][Full Text] [Related]
53. A Vancomycin HPLC Assay for Use in Gut Microbiome Research.
Hu C; Beyda ND; Garey KW
Microbiol Spectr; 2022 Jun; 10(3):e0168821. PubMed ID: 35536037
[TBL] [Abstract][Full Text] [Related]
54. Correlation between Serum Levels of Protein-Bound Uremic Toxins in Hemodialysis Patients Measured by LC/MS/MS.
Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
Mass Spectrom (Tokyo); 2013; 2(Spec Iss):S0017. PubMed ID: 24349936
[TBL] [Abstract][Full Text] [Related]
55. Effects of vancomycin-induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects.
Kim E; Kim AH; Lee Y; Ji SC; Cho JY; Yu KS; Chung JY
Clin Transl Sci; 2021 Sep; 14(5):1955-1966. PubMed ID: 33982376
[TBL] [Abstract][Full Text] [Related]
56. Impact of a Vancomycin-Induced Shift of the Gut Microbiome in a Gram-Negative Direction on Plasma Factor VIII:C Levels: Results from a Randomized Controlled Trial.
Grimnes G; Bhoelan S; Hindberg K; Davids M; Nieuwdorp M; Mollnes TE; Michelsen AE; Ueland T; Brækkan SK; Hansen JB; Tichelaar V
Thromb Haemost; 2022 Apr; 122(4):540-551. PubMed ID: 34428832
[TBL] [Abstract][Full Text] [Related]
57. Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease.
Steenbeke M; Valkenburg S; Gryp T; Van Biesen W; Delanghe JR; Speeckaert MM; Glorieux G
Toxins (Basel); 2021 Nov; 13(11):. PubMed ID: 34822593
[TBL] [Abstract][Full Text] [Related]
58. Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis.
Iguchi A; Yamamoto S; Oda A; Tanaka K; Kazama JJ; Saeki T; Yamazaki H; Ishioka K; Suzutani T; Narita I
Clin Exp Nephrol; 2020 Aug; 24(8):725-733. PubMed ID: 32285213
[TBL] [Abstract][Full Text] [Related]
59. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
60. Can curcumin supplementation reduce plasma levels of gut-derived uremic toxins in hemodialysis patients? A pilot randomized, double-blind, controlled study.
Salarolli RT; Alvarenga L; Cardozo LFMF; Teixeira KTR; de S G Moreira L; Lima JD; Rodrigues SD; Nakao LS; Fouque D; Mafra D
Int Urol Nephrol; 2021 Jun; 53(6):1231-1238. PubMed ID: 33438085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
